Skip to main content
All lobbying filings

Teva Pharmaceuticals USA, Inc.

Teva Pharmaceuticals USA, Inc. filed a Q4 report for Teva Pharmaceuticals USA Inc. on January 14, 2026.

Lobbying for Teva Pharmaceuticals USA Inc.

As filed: TEVA PHARMACEUTICALS USA, INC. for TEVA PHARMACEUTICALS USA INC.

All filings by Teva Pharmaceuticals USA, Inc. · Everything Teva Pharmaceuticals USA Inc. has reported

 Filing · LD-2 quarterly report Q4 report
Reporting period
4th Quarter 2025
Oct 1 - Dec 31 · Posted Jan 14, 2026
Expenses
$360,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
New Jersey

Official filing document

 Government bodies contacted 9
 Lobbying activity 2

Use of Section viii statements in pharmaceutical labeling. Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and legislation to reform pharmacy benefit managers. Patent reform legislation. Proposals related to drug shortages. Reauthorization of the Pandemic and All Hazards Preparedness Act (PAHPA). Proposals related to biosimilar drugs.

A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada (S.J.Res.37). Tariff Transparency Act of 2025 (S.959) and Trump Tariff Transparency Act (H.R.6888).

 Bills named in this filing 3
  • S.J. Res. 37
    A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada.
  • S. 959
    Tariff Transparency Act of 2025
  • H.R. 6888
    Trump Tariff Transparency Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem